Mrna

• A comprehensive review published in The Lancet reaffirms that approved mRNA vaccines are safe and highly effective across diverse populations, including children and immunocompromised patients. • Led by researchers from the University of British Columbia and Imperial College London, the study analyzed data from billions of doses, combining clinical trials with real-world surveillance. • The findings confirm that these vaccines significantly reduce documented SARS-CoV-2 infections, hospitalizations, and mortality within 14 to 42 days post-vaccination.

• A new review published in The Lancet on Tuesday confirms that mRNA vaccines from Pfizer-BioNTech and Moderna are safe and effective. • Led by Manish Sadarangani of B.C. Children's Hospital, researchers analyzed laboratory data, clinical trials, and real-world surveillance from January 2020 through December 2025. • The findings are significant because they validate the scientific and public health impact of mRNA technology during the pandemic.

Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and olderUS health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Continue reading...

• An mRNA vaccine demonstrated potential in a trial with 16 pancreatic cancer patients, reducing recurrence risk post-surgery according to Nature journal. • Eight patients responded positively, stimulating long-term immune responses as noted by Forbes. • Pancreatic cancer has a 12% five-year survival rate; this could transform outcomes for the 66,000 annual US cases if scaled.

• The FDA granted approval on April 7, 2026, to Moderna's mRESVIA vaccine, an mRNA-based shot targeting respiratory syncytial virus (RSV) for adults aged 60 and older. • Clinical trials showed 83.7% efficacy against RSV lower respiratory tract disease in the first season, with data from over 37,000 participants across 22 countries including US sites. • This marks the second mRNA RSV vaccine approved after GSK's Arexvy, aiming to reduce 140,000-160,000 annual US hospitalizations among seniors; CDC review expected soon.